Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) – A systematic review, meta-analysis, and meta-regression
Iis Inayati Rakhmat, Yudith Yunia Kusmala, Dewi Ratih Handayani, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2021) Vol. 15, Iss. 3, pp. 777-782
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Diabetes and COVID-19: The past, the present, and the future
Raymond Pranata, Joshua Henrina, Wilson Matthew Raffaello, et al.
Metabolism (2021) Vol. 121, pp. 154814-154814
Open Access | Times Cited: 87
COVID-19 and Diabetes
Awadhesh Kumar Singh, Kamlesh Khunti
Annual Review of Medicine (2021) Vol. 73, Iss. 1, pp. 129-147
Closed Access | Times Cited: 80
Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis
Nam Nhat Nguyen, Dung Si Ho, Hung Song Nguyen, et al.
Metabolism (2022) Vol. 131, pp. 155196-155196
Open Access | Times Cited: 69
Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis
Tiantian Han, Shaodi Ma, Chenyu Sun, et al.
Archives of Medical Research (2021) Vol. 53, Iss. 2, pp. 186-195
Open Access | Times Cited: 50
The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
Tianli Zhang, Tong Xiang, Shijie Zhang, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 50
Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates
Januar Wibawa Martha, Raymond Pranata, Michael Anthonius Lim, et al.
International Journal of Infectious Diseases (2021) Vol. 108, pp. 6-12
Open Access | Times Cited: 49
The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis
Yidan Chen, Xingfei Lv, Sang Lin, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 34
Obesity and COVID-19: Mechanistic Insights From Adipose Tissue
Lili Yu, Xiaoying Zhang, Sarah Ye, et al.
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 7, pp. 1799-1811
Open Access | Times Cited: 30
Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials
Ahmad Fariz Malvi Zamzam Zein, Catur Setiya Sulistiyana, Wilson Matthew Raffaelo, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2021) Vol. 15, Iss. 4, pp. 102186-102186
Open Access | Times Cited: 31
Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation
Marina V. Shestakova, O. K. Vikulova, A. R. Elfimova, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 19
Noninsulin‐based antihyperglycemic medications in patients with diabetes and COVID‐19: A systematic review and meta‐analysis
Mahmoud Nassar, Hazem Abosheaishaa, Awadhesh Kumar Singh, et al.
Journal of Diabetes (2023) Vol. 15, Iss. 2, pp. 86-96
Open Access | Times Cited: 13
Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives m62A and CD) regulations on patients with cancer and healthy individuals
Jiaman Du, Jiewen Fu, Wenqian Zhang, et al.
International Journal of Oncology (2023) Vol. 62, Iss. 3
Open Access | Times Cited: 13
Integrating micellar HPLC and green analytical chemistry tools in greenness assessment of five commonly Co-formulated antidiabetic drugs
Adel Ehab Ibrahim, Khaled Maged, Magda Elhenawee, et al.
Sustainable Chemistry and Pharmacy (2023) Vol. 35, pp. 101199-101199
Closed Access | Times Cited: 11
Insulin and Metformin Administration: Unravelling the Multifaceted Association with Mortality across Various Clinical Settings Considering Type 2 Diabetes Mellitus and COVID-19
Łukasz Lewandowski, Agnieszka Bronowicka-Szydełko, Maciej Rabczyński, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 605-605
Open Access | Times Cited: 4
Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis
Ahmad Fariz Malvi Zamzam Zein, Wilson Matthew Raffaello
Primary care diabetes (2021) Vol. 16, Iss. 1, pp. 162-167
Open Access | Times Cited: 21
Patho-Physiology of Aging and Immune-Senescence: Possible Correlates With Comorbidity and Mortality in Middle-Aged and Old COVID-19 Patients
Saba Farheen, Sudhanshu Agrawal, Swaleha Zubair, et al.
Frontiers in Aging (2021) Vol. 2
Open Access | Times Cited: 16
Effect of colchicine on mortality in patients with COVID-19 – A systematic review and meta-analysis
Ahmad Fariz Malvi Zamzam Zein, Wilson Matthew Raffaello
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2022) Vol. 16, Iss. 2, pp. 102395-102395
Open Access | Times Cited: 12
Reply to “New‐onset bullous pemphigoid after inactivated Covid‐19 vaccine: Synergistic effect of the Covid‐19 vaccine and vildagliptin”
Carlo Alberto Maronese, Giovanni Di Zenzo, Giovanni Genovese, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 6
Open Access | Times Cited: 11
Non-Insulin Novel Antidiabetic Drugs Mechanisms in the Pathogenesis of COVID-19
Teodor Salmen, Valeria-Anca Pietroșel, Bianca-Margareta Mihai, et al.
Biomedicines (2022) Vol. 10, Iss. 10, pp. 2624-2624
Open Access | Times Cited: 11
Impact of untreated diabetes and COVID-19-related diabetes on severe COVID-19
Emi Ushigome, Masahide Hamaguchi, Kazuki Sudo, et al.
Heliyon (2022) Vol. 8, Iss. 1, pp. e08801-e08801
Open Access | Times Cited: 10
Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands
Rick I. Meijer, Trynke Hoekstra, Niels C. Gritters van den Oever, et al.
Journal of Diabetes & Metabolic Disorders (2021) Vol. 20, Iss. 2, pp. 1155-1160
Open Access | Times Cited: 13
Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus Taking Dipeptidyl Peptidase-4 Inhibitors: Results from a Turkish Nationwide Study
Rıfat Emral, Cem Haymana, İbrahim Demirci, et al.
Diabetes Therapy (2021) Vol. 12, Iss. 11, pp. 2857-2870
Open Access | Times Cited: 13
Narrative review on clinical considerations for patients with diabetes and COVID‐19: More questions than answers
Niki Katsiki, Ricardo Gómez‐Huelgas, Dimitri P. Mikhailidis, et al.
International Journal of Clinical Practice (2021) Vol. 75, Iss. 11
Open Access | Times Cited: 13
Combination of spironolactone and sitagliptin improves clinical outcomes of outpatients with COVID-19: a prospective cohort study
Mohammad Ali Davarpanah, Reuben Adatorwovor, Yasaman Mansoori, et al.
Journal of Endocrinological Investigation (2023) Vol. 47, Iss. 1, pp. 235-243
Open Access | Times Cited: 5
Efficacy and Safety of Sitagliptin in the Treatment of COVID-19
Ehab Mudher Mikhael, Siew Chin Ong, Siti Maisharah Sheikh Ghadzi
Journal of Pharmacy Practice (2022) Vol. 36, Iss. 4, pp. 980-987
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top